Kaival Group Releases Report on Increased Revenue in 2022 Q3

Sep.23.2022
Kaival Group Releases Report on Increased Revenue in 2022 Q3
US e-cigarette company Kaival reported Q3 revenue of $3.8m, up from $3.2m YoY, due to a court decision in August.

US e-cigarette company Kaival Group recently released a report stating that its revenue for the third quarter of the 2022 fiscal year was $3.8 million, up from $3.2 million for the same period last year. Its gross profit was $442,100, compared to a loss of $84,300 for the same period last year.


Kaval Group attributes a portion of its increased revenue to a court ruling in August that put on hold the Food and Drug Administration's (FDA) marketing denial order for the company's non-tobacco flavored Bidi Stick e-cigarette. The US appeals court found that the FDA did not adequately consider Kaval's marketing and access restrictions plan and ordered further review of the company's pre-market tobacco product application while allowing it to continue selling its product.


Eric Mose, President and Chief Operating Officer of Kewal Group, has announced that the company is partnering with Fimo International to sell their products in global markets.


The content of this article is excerpted or reprinted from third-party sources with ownership of copyrights belonging to the original media and authors. If there is any infringement, please contact us for deletion. Any units or individuals wishing to reprint must contact the author and refrain from direct reprinting.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia
HSSP INTL(03626.HK) partners with COTY to establish e-cigarette venture in UAE, expand distribution of Heaven Gifts brand.
Oct.30 by 2FIRSTS.ai
PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Compares Smoke-Free Policies in Three Countries: Japan and New Zealand Lead Tobacco Control, While Thailand’s Ban Stalls Harm Reduction
PMI Malaysia says Japan and New Zealand’s regulated smoke-free alternatives have hastened smoking declines, whereas Thailand’s post-2014 ban drives smokers to cigarettes or the black market—evidence, PMI argues, that pairing regulated alternatives with traditional controls could improve public health faster.
Oct.15 by 2FIRSTS.ai
ceshi
ceshi
Nov.04
German Federal Council calls for ban on disposable vape, government resists change
German Federal Council calls for ban on disposable vape, government resists change
Germany's Federal Council calls for ban on disposable e-cigarettes due to environmental and economic threats, sparking debate.
Oct.14 by 2FIRSTS.ai
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
Overseas e-cig brands are embracing “for her” designs, turning devices into fashion accessories. 2Firsts notes a new “pink tax” emerging through design and pricing, reflecting shifting gender and branding strategies.
Oct.20
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai